Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial

Launched by UNIVERSITY OF MALAGA · Jun 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called whole-body photobiomodulation (PBM) therapy to see if it can help people with Type 2 Diabetes feel better and improve their overall health. PBM therapy uses safe, low-level light to stimulate the body’s cells, which might help manage diabetes in a new way. The study will look at both short-term and long-term effects of this treatment.

Adults between 30 and 70 years old who have been diagnosed with Type 2 Diabetes and have stable blood sugar control (measured by a test called HbA1c between 6.5% and 10%) may be able to join. Participants should have been managing their diabetes with the same medications and lifestyle habits for at least three months before starting the trial. People with serious diabetes complications, sensitivity to light, or certain medications won’t be eligible. Pregnant or breastfeeding women also cannot participate. If you join, you will receive the PBM therapy and be monitored to see how it affects your diabetes and quality of life over time. This study is not yet recruiting participants but aims to find new ways to support those living with Type 2 Diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 30 to 70 years.
• • Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria.
• • HbA1c levels between 6.5% and 10% at screening.
• • Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment
• Exclusion Criteria:
• • Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy).
• • History of photosensitivity or medical conditions exacerbated by light exposure.
• • Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management.
• • Pregnant or lactating women.